Niculescu Dan Alexandru, Baciu Ionela Florina, Capatina Cristina, Galoiu Simona Andreea, Gheorghiu Monica Livia, Radian Serban, Trifanescu Raluca Alexandra, Caragheorgheopol Andra, Coculescu Mihail, Poiana Catalina
Carol Davla University of Medicine and Pharmacy, Bucharest, Romania.
Endokrynol Pol. 2017;68(5):519-523. doi: 10.5603/EP.a2017.0041. Epub 2017 Sep 7.
In Romania, no nationwide data for acromegaly treatment and control rate are available. Our objective was to assess the acromegaly control rate in a tertiary referral centre, which covers an important part of Romanian territory and population of patients with acromegaly.
We reviewed the records of all 164 patients (49 males and 115 females; median age 55 [47, 63.5] years) with newly or previously diagnosed acromegaly, who have been assessed at least once in our tertiary referral centre between January 1, 2012 and March 31, 2016. This sample represents 13.6% of the total expected 1200 Romanian patients with acromegaly and covers 82.9% of the counties in Romania. Control of acromegaly was defined as a random serum growth hormone (GH) < 1 ng/mL and an age-normalised serum insulin-like growth factor-I (IGF-I) value. The GH and IGF-I values used for calculation of the control rate were those at the last evaluation. The same assays for GH and IGF-I measurement were used in all patients.
There were 147 treated and 17 untreated patients. Of the 147 patients assessed after therapy, 137 (93.2%) had pituitary surgery, 116 (78.9%) were on medical treatment at the last evaluation, and 67 (45.5%) had radiotherapy. Seventy-one (48.3%) had a random GH < 1 ng/mL, 54 (36.7%) had a normalised, age-adjusted IGF-I, and 42 (28.6%) had both normal random serum GH and IGF-I.
In Romania, acromegaly benefits from the whole spectrum of therapeutic interventions. However, the control rate remains disappointing.
在罗马尼亚，尚无全国性的肢端肥大症治疗及控制率数据。我们的目标是评估一家三级转诊中心的肢端肥大症控制率，该中心覆盖了罗马尼亚领土的重要部分以及肢端肥大症患者群体。
我们回顾了2012年1月1日至2016年3月31日期间在我们三级转诊中心至少接受过一次评估的所有164例（49例男性和115例女性；中位年龄55 [47, 63.5]岁）新诊断或既往诊断为肢端肥大症的患者记录。该样本占罗马尼亚预计1200例肢端肥大症患者总数的13.6%，覆盖罗马尼亚82.9%的县。肢端肥大症的控制定义为随机血清生长激素（GH）< 1 ng/mL以及年龄标准化的血清胰岛素样生长因子-I（IGF-I）值。用于计算控制率的GH和IGF-I值为最后一次评估时的值。所有患者均采用相同的GH和IGF-I检测方法。
有147例接受治疗的患者和17例未治疗的患者。在治疗后接受评估的147例患者中，137例（93.2%）接受了垂体手术，116例（78.9%）在最后一次评估时接受药物治疗，67例（45.5%）接受了放射治疗。71例（48.3%）随机GH < 1 ng/mL，54例（36.7%）年龄调整后的IGF-I正常，42例（28.6%）随机血清GH和IGF-I均正常。
在罗马尼亚，肢端肥大症受益于全方位的治疗干预措施。然而，控制率仍然令人失望。
